Therapy Areas: Oncology
Atossa Therapeutics' founder and CEO named one of The Top 50 Healthcare Technology CEOs of 2025
22 January 2026 - Clinical-stage biopharmaceutical company Atossa Therapeutics Inc (Nasdaq: ATOS) announced on Wednesday that The Healthcare Technology Report has recognized the company's founder...
Avacta secures FDA clearance for second pre|CISION oncology programme
21 January 2026 - Biopharmaceutical company Avacta Group PLC (AIM: AVCT) announced on Wednesday that it has received clearance from the U.S. Food and Drug Administration of the Investigational New Dru...
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
19 January 2026 - Precision oncology company Guardant Health Inc (Nasdaq: GH) announced on Monday that it has entered into a multi-year strategic collaboration with pharmaceutical firm Merck, known as...
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis
19 January 2026 - Biopharmaceutical company Akeso Inc (HKEX: 9926.HK) announced on Monday that the National Medical Products Administration Center for Drug Evaluation has accepted its supplemental New...
EMA validates Daiichi Sankyo's ENHERTU plus pertuzumab application for first-line HER2 positive metastatic breast cancer
19 January 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that the European Medicines Agency has validated a Type II Variation marketing authorisation applicat...
Immunovia gains California approval for PancreaSure and begins commercial rollout
19 January 2026 - Pancreatic cancer diagnostics company Immunovia AB (STO:IMMNOV) announced on Monday that it has received regulatory approval to offer its PancreaSure test commercially in California,...